Share this :
Post on twitter:
Ironwood IPO: Not quite a knockout
By John McCulloch @ MaRS
February 10, 2010
Not quite a knockout for biotech
Hotly touted Massachusetts biotech Ironwood Pharmaceuticals succeeded in going public on the NASDAQ this week but failed to rake in the amount of cash that industry pundits had predicted. The IPO raised $188 million at a price of $11.25 per share. Not too shabby, but considerably less than the $267 million analysts had envisioned.
Ironwood, which has a Phase III drug (Linoclotide) for irritable bowel syndrome — a large and unsatisfied market — appears to have fallen victim to the weakness in the financial markets triggered by concerns about potential European debt defaults and American unemployment data.
Still, $188 million is nothing to grumble about and if the economic naysayers are correct, it may turn out to be a very prudent step.
The good news: the biotech IPO window is open in the US.
The bad news: it may be closing.
Related Blogs
Clients wow at BioPartnering
Our life sciences and health care practice took three MaRS clients on the road to Vancouver last month to attend the 2011 BioPartnering North America (BPNA) meeting, the first major life sciences bus The future of medicine's so bright
Imagine a world where…
drugs work reliably
no one ever gets sick from their prescriptions
harmful properties are designed out of all new drugs
critically-ill patients entering the ICU expect a po Commercialization Singapore style…
On September 25th I set off to Singapore to speak at the 2010 Innovation Enterprise Week held at Biopolis. 26 hours (and nine action movies) later, I arrived in beautiful Singapore.
It was my first BIO 2010: Impressions
Just got back from the 2010 BIO International Convention in Chicago – the Superbowl of the biotech industry.
Last year’s BIO was a decidedly gloomy affair as investment dropped to levels Overheard at BioFinance
BioFinance – the annual Ontario biotech jamboree – was held at the Toronto Marriot Hotel from April 6-8, 2010.
The mood was noticeably brighter than last year on account of signs of activity in t Canadian biotech balance sheet
BIOTECanada has made further announcements on the financial condition of the Canadian biotechnology industry.
A recent survey indicated that 70% of Canadian biotech companies have at least a year of
Tags: biotechnology, John McCulloch, life sciences
Still, $188 million is nothing to grumble about and if the economic naysayers are correct, it may turn out to be a very prudent step.
